Pharmacopeia Chairman and CEO to Present at SG Cowen's 24th Annual Health Care
Conference On March 10, 2004
PRINCETON, N.J., March 4 /PRNewswire-FirstCall/ -- Pharmacopeia, Inc. today
announced that Dr. Joseph A. Mollica, Chairman, President and CEO, will present
at the SG Cowen 24th Annual Health Care Conference at 9:00 a.m. on March 10,
2004 at The Boston Marriott Copley Place, 110 Huntington Avenue in Boston. A
question and answer session will follow.
An audio webcast of the conference can be accessed at: http://www.corporate-ir.net/ireye/confLobby.zhtml?ticker=ACCL&item_id=860350 Pharmacopeia (http://www.pharmacopeia.com/) is a leader in enabling science and
technology that accelerates and improves the drug discovery and chemical
development processes. Pharmacopeia's Drug Discovery business integrates
proprietary small molecule combinatorial chemistry, medicinal chemistry,
high-throughput screening, in-vitro pharmacology, computational methods and
informatics to discover and optimizelead compounds. Pharmacopeia's software
subsidiary, Accelrys, develops and commercializes molecular modeling and
simulation software for the life sciences and materials research markets,
cheminformatics and decision support systems, and bioinformaticstools including
gene sequence analysis. Pharmacopeia employs approximately 700 people and is
headquartered in Princeton, New Jersey.
Contact:
John J. Hanlon
Chief Financial Officer
(609) 452-3600
When used anywhere in this document, the words "expects," "believes,"
"anticipates," "estimates" and similar expressions are intended to identify
forward-looking statements. Forward-looking statements herein may include
statements addressing future financial and operating results of Pharmacopeia. Pharmacopeia has based these forward-looking statements on its current
expectations about future events. Such statements are subject to risks and
uncertainties including, but not limited to, the successful implementation of
Pharmacopeia's strategic plans, the acceptance of new products, the obsolescence
of existing products, the resolution of existing and potential future patent
issues, additional competition, changes in economic conditions, and other risks
described in documents Pharmacopeia has filed with the Securities and Exchange
Commission, including its most recent report on Form 10-K and subsequent reports
on Form 10-Q. All forward-looking statements in this document are qualified
entirely by the cautionary statements included in this document and such
filings. These risks and uncertainties could cause actual results to differ
materially from results expressed or implied by forward-looking statements
contained in this document. These forward-looking statements speak only as of
the date of this document. Pharmacopeia disclaims any undertaking to publicly
update or revise any forward-looking statements contained herein to reflect any
change in its expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based. DATASOURCE: Pharmacopeia, Inc.
CONTACT: John J. Hanlon, Chief Financial Officer, Pharmacopeia, +1-609-452-3600 or Web site: http://www.pharmacopeia.com/
|